πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Context Therapeutics Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: High

ONPATTRO

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. It targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.

Tags: CNS diseases, RNAi therapeutics, biopharmaceutical, cardio-metabolic diseases, genetic medicines, hepatic diseases

Symbol: ALNY

Recent Price: $236.01

Industry: Biotechnology

CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB

Sector: Healthcare

Employees: 2100

Address: 675 West Kendall Street, Cambridge, MA 02142

Phone: 617 551 8200

Leadership

  • Yvonne Greenstreet, Chief Executive Officer
  • Pushkal Garg, Chief Medical Officer
  • Jeff Poulton, Chief Financial Officer
  • Kelley Boucher, Chief Human Resource Officer
  • Timothy Maines, Chief Technical Operations and Quality Officer
  • Tolga Tanguler, Chief Commercial Officer
  • Piyush Sharma, Chief Ethics & Compliance Officer
  • Evan Lippman, Chief Corporate Development & Strategy Officer
  • Kevin Fitzgerald, Chief Scientific Officer
  • Amy W. Schulman, Chair
  • Dennis A. Ausiello,
  • Carolyn Bertozzi,
  • Michael W. Bonney,
  • Olivier Brandicourt,
  • Margaret A. Hamburg,
  • Peter N. Kellogg,
  • David E.I. Pyott,
  • Colleen F. Reitan,
  • Phillip A. Sharp,
  • Elliott Sigal,

Last updated: 2024-12-31

Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Stenoparib, Dovitinib, IXEMPRA, Li Pla Cis, 2X-111

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing oncology therapeutics using companion diagnostics and drug response predictor technology.

Tags: biopharmaceutical, clinical trials, companion diagnostics, oncology, therapeutics

Symbol: ALLR

Recent Price: $1.12

Industry: Biotechnology

CEO: Mr. Thomas H. Jensen

Sector: Healthcare

Employees: 5

Address: 210 Broadway, Cambridge, MA 02139

Phone: 401 426 4664

Last updated: 2024-12-31

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

XMT-1592

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADC) for treating cancer patients with unmet needs. It specializes in ADC products like XMT-1592 and has strategic partnerships for the advancement of its innovative therapeutics.

Tags: ADC, XMT-1592, biopharmaceutical, cancer treatment, clinical trials, partnerships

Symbol: MRSN

Recent Price: $1.42

Industry: Biotechnology

CEO: Dr. Martin H. Huber M.D.

Sector: Healthcare

Employees: 123

Address: 840 Memorial Drive, Cambridge, MA 02139

Phone: 617 498 0020

Leadership

  • David Mott, Chairman of the Board
  • Lawrence Alleva, Retired Partner, PriceWaterhouseCoopers
  • Willard H. Dere, MD, Professor Emeritus of Internal Medicine, University of Utah
  • Allene M. Diaz, Independent Commercial Strategy and Portfolio Management Consultant, AMD Consulting
  • Andrew Hack MD, PhD, Managing Director, Bain Capital Life Sciences
  • Kristen M. Hege, MD, Retired Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb Company
  • Anna Protopapas, Chair of the board of directors of Nuvalent
  • Martin Huber, MD, President and Chief Executive Officer

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Omeros Corporation

Omeros Corporation logo
Market Cap: Low
Employees: Low

Narsoplimab

Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.

Tags: Narsoplimab, addiction, biopharmaceutical, clinical trials, drug development, immune system, therapeutics

Symbol: OMER

Recent Price: $9.74

Industry: Biotechnology

CEO: Dr. Gregory A. Demopulos M.D.

Sector: Healthcare

Employees: 198

Address: The Omeros Building, Seattle, WA 98119

Phone: 206 676 5000

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

PYX-106, PYX-102, PYX-201, PYX-202, PYX-203

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.

Tags: antibody drug conjugate, biopharmaceutical, cancer therapy, immune-oncology, solid tumors

Symbol: PYXS

Recent Price: $1.56

Industry: Biotechnology

CEO: Dr. Lara S. Sullivan M.D., MBA

Sector: Healthcare

Employees: 55

Address: 35 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 221 9059

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

Acrivon Predictive Precision Proteomics

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.

Tags: ACR-368, CHK1, CHK2, biopharmaceutical, clinical trials, oncology, precision medicine, proteomics

Symbol: ACRV

Recent Price: $5.41

Industry: Biotechnology

CEO: Dr. Peter Blume-Jensen M.D., Ph.D.

Sector: Healthcare

Employees: 58

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617-207-8979

Last updated: 2024-12-31

Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ATRN-119

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Tags: DNA damage response, biopharmaceutical, cancer therapeutics, clinical trial

Symbol: APRE

Recent Price: $3.48

Industry: Biotechnology

CEO: Dr. Oren Gilad Ph.D.

Sector: Healthcare

Employees: 7

Address: 535 Boylston St., Boston, MA 02116

Phone: 617-463-9385

Last updated: 2024-12-31

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Endoxifen

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.

Tags: COVID-19, Endoxifen, biopharmaceutical, breast cancer, infectious diseases, oncology

Symbol: ATOS

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.

Sector: Healthcare

Employees: 12

Address: 107 Spring Street, Seattle, WA 98104

Phone: 206 588 0256

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Context Therapeutics Inc.

Context Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

onapristone extended release (ONA-XR)

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for women in the United States. Its main product, ONA-XR, is aimed at resistant female hormone-dependent cancers.

Tags: CLDN6, T-cell-mediated therapy, biopharmaceutical, cancer treatment, monoclonal antibody, oncology, progesterone receptor, women's health

Symbol: CNTX

Recent Price: $1.06

Industry: Biotechnology

CEO: Mr. Martin A. Lehr

Sector: Healthcare

Employees: 5

Address: 2001 Market Street, Philadelphia, PA 19103

Phone: 267 225 7416

Last updated: 2024-12-31

Cardiff Oncology, Inc.

Cardiff Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

Onvansertib

Cardiff Oncology, Inc. is a clinical-stage oncology company developing treatment medicine for cancer patients, featuring lead drug candidate onvansertib, targeting various cancers including colorectal cancer. The company is headquartered in San Diego, California.

Tags: biotechnology, cancer treatment, clinical trials, oncology, pharmaceuticals

Symbol: CRDF

Recent Price: $4.26

Industry: Biotechnology

CEO: Dr. Mark Erlander Ph.D.

Sector: Healthcare

Employees: 31

Address: 11055 Flintkote Avenue, San Diego, CA 92121

Phone: 858 952 7570

Last updated: 2024-12-31

Onconetix, Inc.

Onconetix, Inc. logo
Market Cap: Lowest
Employees: Lowest

Entadfi

Onconetix, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing transformative therapies to address global health challenges. The company’s products include Entadfi for benign prostatic hyperplasia and various innovative vaccine candidates.

Tags: Entadfi, biotechnology, healthcare, pharmaceutical, therapies, vaccines

Symbol: ONCO

Recent Price: $0.44

Industry: Biotechnology

CEO: Dr. Ralph Schiess Ph.D.

Sector: Healthcare

Employees: 12

Address: 201 East Fifth Street, Cincinnati, OH 45202

Phone: 513 620 4101

Last updated: 2024-12-31

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

ONS-5010

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing monoclonal antibodies for ophthalmic indications, with its lead product candidate ONS-5010 in Phase-III clinical trial for treating wet age-related macular degeneration and other retina diseases.

Tags: biopharmaceutical, clinical trial, monoclonal antibodies, ophthalmic, retina diseases

Symbol: OTLK

Recent Price: $1.86

Industry: Biotechnology

CEO: Mr. C. Russell Trenary III

Sector: Healthcare

Employees: 24

Address: Building F, Iselin, NJ 08852

Phone: 609 619 3990

Leadership

  • Randy Thurman, Executive Chairman
  • Yezan Haddadin, Member of the Board of Directors
  • Kurt J. Hilzinger, Member of the Board of Directors
  • Julia A. Haller, MD, Member of the Board of Directors
  • C. Russell Trenary III, President, Chief Executive Officer, and Member of the Board
  • Lawrence A. Kenyon, Chief Financial Officer and Member of the Board
  • Faisal G. Sukhtian, Executive Director
  • Julian Gangolli, Member of the Board of Directors
  • Gerd Auffarth, MD, Member of the Board of Directors
  • Andong Huang, Vice President, Business Development

Last updated: 2024-12-31

XOMA Corporation

XOMA Corporation logo
Market Cap: Low
Employees: Lowest

Pre-commercial therapeutic candidates

XOMA Corporation operates as a biotechnology royalty aggregator focusing on enhancing human health by acquiring potential future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotech companies. With a portfolio of approximately 70 assets, it focuses on early to mid-stage clinical assets with commercial sales potential.

Tags: Biotechnology, Clinical Assets, Pharmaceutical, Royalty Aggregator, Therapeutic Candidates

Symbol: XOMA

Recent Price: $26.09

Industry: Biotechnology

CEO: Mr. Owen P. Hughes Jr.

Sector: Healthcare

Employees: 13

Address: 2200 Powell Street, EmeryVille, CA 94608

Phone: 510 204 7200

Last updated: 2024-12-31